Luciano De Petrocellis

TL;DR: Peripheral endocannabinoid overactivity might explain why CB(1) blockers cause weight-loss independent reduction of lipogenesis, of hypoadiponectinemia, and of hyperinsulinemia in obese animals and humans.

TL;DR: How anandamide and 2-AG differential actions at TRPV1 and cannabinoid receptors contribute to making this signalling system a versatile tool available to organisms to fine-tune homeostasis is discussed.

TL;DR: Findings show for the first time a derangement in the production of the endogenous cannabinoid AEA in drug-free symptomatic women with anorexia nervosa or with binge-eating disorder, which suggests a possible involvement of AEE in the mediation of the rewarding aspects of the aberrant eating behaviors occurring in AN and BED.

TL;DR: Exogenous anandamide is formed on stimulation of metabotropic receptors coupled to the phospholipase C/inositol 1,4,5‐triphosphate pathway and then signals to TRPV1 channels, a novel intracellular function of an andamide that may precede its action at cannabinoid receptors, and might be relevant to its control over neurotransmitter release.

TL;DR: The latest data on the non- CB1, non-CB2 receptors suggested so far for endocannabinoids and plant or synthetic cannabinoids are reviewed, with special emphasis on uncharacterized or orphan G-protein-coupled receptors as well as on transient receptor potential channels.